What is Wedbush’s Forecast for RARE FY2027 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities researchers at Wedbush boosted their FY2027 earnings per share estimates for Ultragenyx Pharmaceutical in a research report issued to clients and investors on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn $1.05 per share for the year, up from their prior estimate of $1.04. Wedbush has a “Neutral” rating and a $48.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.14) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s FY2028 earnings at $1.92 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.45) by $0.05. The business had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company’s revenue for the quarter was up 42.3% on a year-over-year basis. During the same period last year, the company earned ($2.23) EPS.

Several other equities research analysts also recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday. JPMorgan Chase & Co. reduced their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 21st. HC Wainwright reiterated a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. Piper Sandler raised their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, January 13th. Finally, TD Cowen raised their price objective on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $92.43.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE opened at $44.05 on Friday. The business has a 50 day simple moving average of $44.56 and a 200-day simple moving average of $49.57. Ultragenyx Pharmaceutical has a 1 year low of $37.02 and a 1 year high of $60.37. The firm has a market capitalization of $4.07 billion, a price-to-earnings ratio of -6.81 and a beta of 0.58.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. True Wealth Design LLC bought a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth $43,000. Values First Advisors Inc. purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter worth $56,000. Wilmington Savings Fund Society FSB purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter worth $83,000. Nomura Asset Management Co. Ltd. purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter worth $93,000. Finally, Capital Performance Advisors LLP purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter worth $107,000. 97.67% of the stock is owned by institutional investors.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 11,727 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the transaction, the chief executive officer now directly owns 2,183,985 shares of the company’s stock, valued at approximately $92,229,686.55. The trade was a 0.53 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.80% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.